191 related articles for article (PubMed ID: 29535425)
1. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
Landtblom AR; Bower H; Andersson TM; Dickman PW; Samuelsson J; Björkholm M; Kristinsson SY; Hultcrantz M
Leukemia; 2018 Oct; 32(10):2203-2210. PubMed ID: 29535425
[TBL] [Abstract][Full Text] [Related]
2. Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.
Hultcrantz M; Björkholm M; Dickman PW; Landgren O; Derolf ÅR; Kristinsson SY; Andersson TML
Ann Intern Med; 2018 Mar; 168(5):317-325. PubMed ID: 29335713
[TBL] [Abstract][Full Text] [Related]
3. Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.
Hultcrantz M; Wilkes SR; Kristinsson SY; Andersson TM; Derolf ÅR; Eloranta S; Samuelsson J; Landgren O; Dickman PW; Lambert PC; Björkholm M
J Clin Oncol; 2015 Jul; 33(20):2288-95. PubMed ID: 26033810
[TBL] [Abstract][Full Text] [Related]
4. Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.
Herr MM; Schonfeld SJ; Dores GM; Withrow DR; Tucker MA; Curtis RE; Morton LM
J Natl Cancer Inst; 2018 Nov; 110(11):1248-1258. PubMed ID: 29659938
[TBL] [Abstract][Full Text] [Related]
5. Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients.
Landtblom AR; Andersson TM; Dickman PW; Smedby KE; Eloranta S; Batyrbekova N; Samuelsson J; Björkholm M; Hultcrantz M
Leukemia; 2021 Feb; 35(2):476-484. PubMed ID: 32546727
[TBL] [Abstract][Full Text] [Related]
6. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study.
Pedersen KM; Bak M; Sørensen AL; Zwisler AD; Ellervik C; Larsen MK; Hasselbalch HC; Tolstrup JS
Cancer Med; 2018 Nov; 7(11):5796-5802. PubMed ID: 30318865
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms.
Zhang Y; Han Y; Teng G; Du C; Gao S; Yuan W; Zhang L; Bai J
Cancer Med; 2023 Apr; 12(8):9236-9246. PubMed ID: 36727544
[TBL] [Abstract][Full Text] [Related]
8. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
9. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
Hong J; Lee JH; Byun JM; Lee JY; Koh Y; Shin DY; Lee JO; Hwang SM; Choi HS; Kim I; Yoon SS; Bang SM
Blood Adv; 2019 Nov; 3(22):3700-3708. PubMed ID: 31765478
[TBL] [Abstract][Full Text] [Related]
10. Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.
Bak M; Sørensen TL; Flachs EM; Zwisler AD; Juel K; Frederiksen H; Hasselbalch HC
JAMA Ophthalmol; 2017 Aug; 135(8):835-843. PubMed ID: 28655032
[TBL] [Abstract][Full Text] [Related]
11. Non-melanoma skin cancer as a clinical marker for internal malignancies: a nationwide population-based cohort study.
Yun SJ; Bae JM; Kim H; Park BC; Kim JS; Seo SH; Ahn HH; Lee DY; Kim YC; Park HJ; Chung KY
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):746-753. PubMed ID: 31494979
[TBL] [Abstract][Full Text] [Related]
12. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis.
Pettersson H; Knutsen H; Holmberg E; Andréasson B
Eur J Haematol; 2015 Feb; 94(2):152-6. PubMed ID: 25039361
[TBL] [Abstract][Full Text] [Related]
13. Obesity and related risk of myeloproliferative neoplasms among israeli adolescents.
Leiba A; Duek A; Afek A; Derazne E; Leiba M
Obesity (Silver Spring); 2017 Jul; 25(7):1187-1190. PubMed ID: 28500663
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France.
Jabagi MJ; Vey N; Goncalves A; Le Tri T; Zureik M; Dray-Spira R
JAMA Netw Open; 2019 Jan; 2(1):e187147. PubMed ID: 30657534
[TBL] [Abstract][Full Text] [Related]
15. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
Hansen IO; Sørensen AL; Hasselbalch HC
Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
[TBL] [Abstract][Full Text] [Related]
16. The association between malignant melanoma and noncutaneous malignancies.
Wu YH; Kim GH; Wagner JD; Hood AF; Chuang TY
Int J Dermatol; 2006 May; 45(5):529-34. PubMed ID: 16700785
[TBL] [Abstract][Full Text] [Related]
17. Association between tumor characteristics and second primary cancers with cutaneous melanoma survival: A nationwide cohort study.
Zheng G; Chattopadhyay S; Sundquist K; Sundquist J; Försti A; Hemminki A; Hemminki K
Pigment Cell Melanoma Res; 2020 Jul; 33(4):625-632. PubMed ID: 32012479
[TBL] [Abstract][Full Text] [Related]
18. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
Marees T; Moll AC; Imhof SM; de Boer MR; Ringens PJ; van Leeuwen FE
J Natl Cancer Inst; 2008 Dec; 100(24):1771-9. PubMed ID: 19066271
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms.
Potthoff A; Attia D; Pischke S; Mederacke I; Beutel G; Rifai K; Deterding K; Heiringhoff K; Klempnauer J; Strassburg CP; Manns MP; Bahr MJ
Liver Int; 2015 Aug; 35(8):2042-9. PubMed ID: 25736096
[TBL] [Abstract][Full Text] [Related]
20. Malaria and risk of lymphoid neoplasms and other cancer: a nationwide population-based cohort study.
Wyss K; Granath F; Wångdahl A; Djärv T; Fored M; Naucler P; Färnert A
BMC Med; 2020 Oct; 18(1):296. PubMed ID: 33121475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
